Effects of Pharmacologic Dose of Resveratrol Supplementation on Oxidative/Antioxidative Status Biomarkers in Nonalcoholic Fatty Liver Disease Patients: A Randomized, Double-Blind, Placebo-Controlled Trial

Advanced Pharmaceutical Bulletin
Q1
Jun 2018
Citations:42
Influential Citations:4
Interventional (Human) Studies
93
S2 IconPDF Icon

Enhanced Details

Methods
60 NAFLD patients (aged 20-60 years; BMI 25-35 kg/m2; 41 males, 19 females) diagnosed by liver ultrasonography; randomized, double-blind, placebo-controlled clinical trial.
Intervention
600 mg resveratrol daily (two 300 mg capsules of pure trans-resveratrol) for 12 weeks; oral administration.
Results
No significant change in oxidative/anti-oxidative status or liver enzymes with resveratrol vs placebo after 12 weeks. MDA, ox-LDL, TAC, SOD, GSH-Px, ALT, AST, GGT, and ALP showed no significant differences (P>0.05). BMI decreased modestly with resveratrol versus placebo (mean difference ≈ -0.31 kg/m2; 95% CI -0.64 to -0.02; P<0.05). Conclusion: 600 mg/day resveratrol for 12 weeks does not improve oxidative/anti-oxidative status in NAFLD; any observed BMI reduction is small and does not support antioxidant benefits at this regimen.
Limitations
Ultrasound-based diagnosis of NAFLD; single-center study; relatively small sample with 9 dropouts (60 randomized, 51 completed); short duration (12 weeks); participants largely metabolically healthy at baseline (liver enzymes normal), which may limit responsiveness; results may not generalize to other doses or durations.

Abstract

Purpose: Despite a proposed role for oxidative stress in the pathogenesis of nonalcoholic fatty liver disease (NAFLD), antioxidant approaches have not been sufficiently investigated in human NAFLD management. Resveratrol has been reported to possess ...